Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma

Jane N. Winter*

*Corresponding author for this work

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin®) and iodine 1131 tositumomab (Bexxar®), has the potential to increase the cure rate for patients with CD20+ B-cell malignancies who are undergoing autologous hematopoietic stem cell transplantation. The results of phase I and II trials suggest that radioimmunoconjugates can be safely combined with high-dose chemotherapy, although the optimal approach remains to be established. This review focuses on the use of 90Y ibritumomab tiuxetan combined with high-dose chemotherapy in the setting of autologous hematopoietic stem cell transplantation.

Original languageEnglish (US)
Pages (from-to)S22-S26
JournalClinical Lymphoma
Volume5
Issue numberSUPPL. 1
DOIs
StatePublished - Oct 2004

Keywords

  • Autologous stem cell transplantation
  • Radioimmunotherapy
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

  • Cite this